Cephalon To Develop Oncology Franchise Following Acquisition Of CTI’s Trisenox

Cephalon will build a hematology franchise around the Trisenox acquisition; the company may add its Phase II tyrosine kinase inhibitor (CEP-701) and Salmedix’ lymphoma treatment Treanda when that acqusition closes. CTI is selling Trisenox to reinvest in its late-stage pipeline.